Lutz Wollin
6PUBLICATIONS
12CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Jul 25, 2025
Proof of Pharmacology, Safety, and Pharmacokinetics of the Novel TRPA1 Antagonist BI 1839100: A Randomized, Placebo-Controlled, Parallel Group, First-In-Human Study in Healthy Male Participants.Marella C E van Ruissen, Sebastiaan J W van Kraaij, Jana Wolfova
|Oct 27, 2022
Nintedanib Reduces Muscle Fibrosis and Improves Muscle Function of the Alpha-Sarcoglycan-Deficient Mice.Jorge Alonso-Pérez, Ana Carrasco-Rozas, Maria Borrell-Pages
|Aug 04, 2022
Nintedanib modulates type III collagen turnover in viable precision-cut lung slices from bleomycin-treated rats and patients with pulmonary fibrosis.Christina Hesse, Valerie Beneke, Sebastian Konzok
|Apr 06, 2022
Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis-associated interstitial lung disease.Lutz Wollin, Jörg Hw Distler, Christopher P Denton
|Apr 28, 2020
Effects of Nintedanib in an Animal Model of Liver Fibrosis.Lutz Wollin, Dieudonnée Togbe, Bernhard Ryffel
|Mar 28, 2020
TNF-α and IL-10 Control CXCL13 Expression in Human Macrophages.Nessrine Bellamri, Roselyne Viel, Claudie Morzadec
Pageof 1
Frequent Collaborators
1 joint publications
Stéphane Jouneau
1 joint publications
Jorge Alonso-Pérez
1 joint publications
Esther Fernández-Simón
1 joint publications
Lina Badimon
1 joint publications
Eduard Gallardo
1 joint publications
Montse Olivé
1 joint publications
Xavier Suárez-Calvet
1 joint publications
Marella C E van Ruissen
1 joint publications
Sebastiaan J W van Kraaij
1 joint publications
Jana Wolfova
